These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Gono T; Matsuda M; Shimojima Y; Ishii W; Koyama J; Sakashita K; Koike K; Hoshii Y; Ikeda S Amyloid; 2004 Dec; 11(4):245-56. PubMed ID: 15678759 [TBL] [Abstract][Full Text] [Related]
29. [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases]. Mseddi-Hdiji S; Haddouk S; Ben Ayed M; Tahri N; Elloumi M; Baklouti S; Hachicha J; Krichen MS; Bahloul Z; Masmoudi H Pathol Biol (Paris); 2005 Feb; 53(1):19-25. PubMed ID: 15620605 [TBL] [Abstract][Full Text] [Related]
30. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357 [TBL] [Abstract][Full Text] [Related]
31. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330 [TBL] [Abstract][Full Text] [Related]
32. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623 [TBL] [Abstract][Full Text] [Related]
33. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795 [TBL] [Abstract][Full Text] [Related]
34. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
35. The systemic amyloidoses. Falk RH; Comenzo RL; Skinner M N Engl J Med; 1997 Sep; 337(13):898-909. PubMed ID: 9302305 [No Abstract] [Full Text] [Related]
38. Primary amyloidosis presenting as renal infarction. Arias M; Abreu JA; Iglesias A; Longo J; Lecumberri F; Vega F Eur Radiol; 1996; 6(3):346-8. PubMed ID: 8798004 [TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. Bladé J; Lust JA; Kyle RA J Clin Oncol; 1994 Nov; 12(11):2398-404. PubMed ID: 7964956 [TBL] [Abstract][Full Text] [Related]